Google
MRKR 株価分析 — Marker Therapeutics Inc (Healthcare >> Biotechnology)
MRKR に関するよくある質問
MRKRのROE（自己資本利益率）は？
Marker Therapeutics IncのROEは-78.98%です。
MRKRの配当利回りは？
Marker Therapeutics Incの配当利回りは0.00%です。
MRKRの品質スコア（Quality Score）は？
当社のAIはMRKRの総合財務品質を100点中8点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
MRKRは今が買い時ですか？
当社AIのタイミングスコアは100点中0点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
MRKRはどのセクターに属しますか？
Marker Therapeutics IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
MRKR AI Analysis Summary
Our AI summary for MRKR: Marker Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -78.98%, a dividend yield of 0.00%. Its financial Quality Score stands at 8/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.12
Price
-0.02
(-1.75%)
Day Change
|
|
|---|
MRKR, ファンダメンタルスコアはnot good ( ファンダメンタル = 8) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.12 |
| PBV / Sector |
1.38 / 5.21
GOOD
|
| Earning Per Share | -0.64 |
| PE / Sector |
N/A / 21.00
|
| PEG or PE/Growth / Sector |
N/A / 1.11
|
| Average 1M Daily Value |
0.06 M
GREAT
|
| Average 1W Daily Value |
0.06 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-07 08:12:01 |
| Symbol | MRKR |
| Name | MARKER THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 16.67 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 19.01 / 9,672.56 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2450 Holcombe Blvd, Houston, TX, United States, 77021
Phone: 713 400 6400
Website: https://markertherapeutics.com
Sector: Healthcare >> Biotechnology
Description: Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
